CompletedNot Applicable

Mass Drug Administration With Dihydroartemisinin + Piperaquine for Reducing Malaria in Southern Zambia

Zambia2,430 participantsStarted 2014-09

Plain-language summary

To quantify the relative effectiveness, cost, and cost-effectiveness of fMDA and MDA with DHAp against no mass treatment for reducing P. falciparum parasite prevalence, confirmed OPD malaria case incidence and cohort infection incidence in areas of high and low malaria transmission and in a program-relevant manner that will permit adoption and adaptation for wider-scale deployment.

Who can participate

Age range3 Months

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * anyone not excluded and consenting Exclusion Criteria: * contraindications from manufacturer for medications including currently taking haloperidol, artane, Phenergan (Promethazine), chlorpromazine, erythromycin, Azithromycin, clarithromycin, Ketoconazole, fluconazole, mefloquine (as prophylaxis), lumefantrine (in Coartem), quinine, Septrin * anyone seriously ill * currently taking antimalarial medicines * allergy to artemisinin drugs * pregnant women in first trimester * children under 3 months of age * reported heart condition

What they're measuring

Parasite prevalence during the high transmission season among children <6 years old (excluding neonates <1 month)

Timeframe: For up to 12 months

P.falciparum infection incidence rate among individuals ≥3 months

Timeframe: For up to 12 months

Trial details

NCT IDNCT02329301

SponsorPATH

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2016-06

View on ClinicalTrials.gov More Malaria trials